nootropic

Nootropics are substances purported to improve cognitive function, especially learning, memory, attention, or creativity, with minimal side effects. The term was coined by Romanian psychologist and chemist Corneliu Giurgea in the 1970s. Originally it described compounds that enhance learning and memory, protect neurons, and show low toxicity. In current usage, the label covers a broad range of substances, including prescription drugs, dietary supplements, and other compounds, with varying levels of evidence.

Common categories include prescription stimulants such as methylphenidate and modafinil; natural products such as caffeine, L-theanine, bacopa, and ginkgo; racetams (piracetam, aniracetam); and choline sources (alpha-GPC, CDP-choline). Many marketed nootropics lack robust clinical evidence for healthy individuals, and efficacy varies across substances and tasks.

Evidence for healthy adults generally shows small or inconsistent effects on attention, memory, or executive function, with results heavily influenced by study design and placebo effects. Some substances have clearer evidence in specific populations, such as modafinil in sleep-deprived individuals and methylphenidate in ADHD.

Regulation varies by country. In the United States, many nootropics are sold as dietary supplements with limited pre-market testing; others are prescription medications. Potential risks include insomnia, anxiety, cardiovascular effects, interactions with other drugs, and, for stimulants, dependence. Dosing and product quality can vary.

Overall, while some agents may offer modest cognitive benefits in certain contexts, robust, long-term enhancements in healthy people are not established. The field continues to study mechanisms, efficacy, safety, and the ethical implications of cognitive enhancement.